British Journal of Clinical Pharmacology

Article	Citations
The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence	176
Recent developments of HDAC inhibitors: Emerging indications and novel molecules	159
Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis	58
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis	56
Underrepresentation of the elderly in clinical trials, time for action	56
Machine learning in pharmacometrics: Opportunities and challenges	48
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls	48
Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects	48
Warfarin and food, herbal or dietary supplement interactions: A systematic review	47
Potential role of IL‐17 blocking agents in the treatment of severe COVID‐19?	39
Warfarin dosing algorithms: A systematic review	39
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports	38
Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports	38
Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections	37
Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database	36
Strategies to reduce use of antidepressants	36
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19	36
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO	35
Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities	35
Drug–drug interactions with warfarin: A systematic review and meta‐analysis	35
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale	35
Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle‐aged people treated for diabetes	34
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis	34
Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists	34
TDM is dead. Long live TCI!	34

Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure	32
Changes in antibiotic prescribing following COVID‐19 restrictions: Lessons for post‐pandemic antibiotic stewardship	32
Effect of lipophilicity on drug distribution and elimination: Influence of obesity	31
The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial	31
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours	31
Advances and roadblocks in the treatment of malaria	30
A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans	30
Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin	29
Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole	29
Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19	29
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy	29
Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study	28
Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder	28
CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis	28
Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression	27
Pharmacovigilance in low‐ and middle‐income countries: A review with particular focus on Africa	27
A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator	27
Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions	27
Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R	26
Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population‐based nested case–control studies	26
Liver and kidney function in patients with Covid‐19 treated with remdesivir	26
A systematic review of methods used to conduct decentralised clinical trials	26
A systematic review of economic evaluations of advanced therapy medicinal products	26
Impact of the Goal‐directed Medication Review Electronic Decision Support System on Drug Burden Index: A cluster‐randomised clinical trial in primary care	26
The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: A randomized controlled trial	25
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines	25
Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals	25
Infant drug exposure via breast milk	25
The problem of look‐alike, sound‐alike name errors: Drivers and solutions	25
Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology	25
Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders	25
The environmental impact of inhalers for asthma: A green challenge and a golden opportunity	25
Ethical issues in therapeutic use and research in pregnant and breastfeeding women	24
Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis	24
Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients	24
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology	24
Drug‐induced peripheral oedema: An aetiology‐based review	24
Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis	24
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies	24
Is there scope for better individualisation of anthracycline cancer chemotherapy?	23
Health equality, race and pharmacogenomics	23
Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study	23
Emerging therapeutic drug monitoring of anti‐infective agents in Australian hospitals: Availability, performance and barriers to implementation	22
Performance of creatinine‐based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment	22
Chimeric antigen receptor T‐cell therapies: Optimising the dose	22
The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis	22
Pregabalin poisoning and rising recreational use: a retrospective observational series	22
Pharmacological profile and effects of mitotane in adrenocortical carcinoma	22
Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study	22
Metamizole: An underrated agent causing severe idiosyncratic drug‐induced liver injury	22

Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study	22
Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors	22
The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation	21
Dosing will be a key success factor in repurposing antivirals for COVID‐19	21
Model‐informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID‐19	20
A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single‐dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers	20
Community‐based pharmacists' role in deprescribing: A systematic review	20
Antiplatelet therapy in cardiovascular disease: Current status and future directions	20
Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta‐analysis	19
Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis	19
Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta‐analysis of observational studies	19
First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist	19
Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients	19
ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study	19
Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review	19
Review of pharmacological options for the treatment of Chagas disease	19
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement	19
Oral drug dosing following bariatric surgery: General concepts and specific dosing advice	19
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White	18
Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects	18
Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients	18
Hypertension: Current trends and future perspectives	18
TEOS: A framework for constructing operational definitions of medication adherence based on Timelines–Events–Objectives–Sources	18
The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple‐dose trial	18
Prior use of therapeutic anticoagulation does not protect against COVID‐19 related clinical outcomes in hospitalized patients: A propensity score‐matched cohort study	18
Clinical implementation of pharmacogenetics and model‐informed precision dosing to improve patient care	18
Hospitalization for COVID‐19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study	18
Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches	17
Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles	17
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective	17
Safety and immunogenicity of Fc‐EDA, a recombinant ectodysplasin A1 replacement protein, in human subjects	17
Sulfate conjugation may be the key to hepatotoxicity in paracetamol overdose	17
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake	17
An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia	17
Association study between herpes zoster reporting and mRNA COVID‐19 vaccines (BNT162b2 and mRNA‐1273)	17
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	17
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation	17
Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated	17
Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD‐REIN cohort study	17
INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID‐19 (INHALE‐HEP): Protocol and statistical analysis plan for an investigator‐initiated international metat	17
The COVID‐19 ibuprofen controversy: A systematic review of NSAIDs in adult acute lower respiratory tract infections	17
Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis	17
Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices	16
Disease‐modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database	16
Chimeric antigen receptor T‐cell therapy toxicities	16
Medication‐related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications	16
Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: Electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization	16
Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials	16
A semi‐mechanistic model based on glutathione depletion to describe intra‐individual reduction in busulfan clearance	16
A pilot randomised placebo‐controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability	16
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease	16
Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers	16
COVID‐19 and (hydroxy)chloroquine–azithromycin combination: Should we take the risk for our patients?	16
Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID‐19: A multicentre case series of 98 patients	16
Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria	16
A case of acute necrotising pancreatitis following the second dose of Pfizer‐BioNTech COVID‐19 mRNA vaccine	16
Pharmacist‐led interventions to reduce adverse drug events in older people living in residential aged care facilities: A systematic review	16
A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population	16
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials	15
Do anti‐tumour necrosis factor‐α biologics affect subclinical measures of atherosclerosis and arteriosclerosis? A systematic review	15
Bisphosphonate nephropathy: A case series and review of the literature	15
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil to	15
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target	15
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy par	15
Monitoring the community use of antibiotics in Italy within the National Action Plan on antimicrobial resistance	15
Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review	15
Population pharmacokinetics and exposure‐response analysis of tigecycline in patients with hospital‐acquired pneumonia	15
Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication	15
Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta‐analysis	15
Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics	15
A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID‐19 (SARS‐COV‐2) treatments	15
Ten‐year trend of opioid and nonopioid analgesic use in the French adult population	15
Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans	15
Estimating the potential impact of implementing pre‐emptive pharmacogenetic testing in primary care across the UK	15
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy	15
Who prescribes drugs to patients: A Danish register‐based study	14
Antihypertensive medications and COVID‐19 diagnosis and mortality: Population‐based case‐control analysis in the United Kingdom	14
Ketamine treatment for refractory anxiety: A systematic review	14
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist	14
Ensuring access to safe, effective, and affordable cannabis‐based medicines	14

Riociguat: Clinical research and evolving role in therapy	14
Advancing structured decision‐making in drug regulation at the FDA and EMA	14
Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta‐analysis	14
The Dutch chain approach on pharmaceuticals in water: Stakeholders acting together to reduce the environmental impact of pharmaceuticals	14
The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour	14
Measuring prescription opioid misuse and its consequences	14
Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future	14
The association between proton pump inhibitor use and systemic anti‐tumour therapy on survival outcomes in patients with advanced non‐small cell lung cancer: A systematic review and meta‐analysis	14
A systematic review and combined meta‐analysis of concentration of oral amisulpride	14
Population pharmacokinetics of mycophenolic acid in paediatric patients	14
Proton pump inhibitors and risk of all‐cause and cause‐specific mortality: A cohort study	14
Effect of ursodeoxycholic acid on liver markers: A systematic review and meta‐analysis of randomized placebo‐controlled clinical trials	14
Drug‐drug interaction between warfarin and statins: A Danish cohort study	14
Impact of pharmacist‐led medication therapy management in ambulatory elderly patients with chronic diseases	14
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects	14
Achievements and challenges of the Sakigake designation system in Japan	13
Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery	13
A framework for simplification of quantitative systems pharmacology models in clinical pharmacology	13
The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study	13
Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on clinical trials and the COVID‐19 pandemic	13
Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children	13
Long‐term trajectories of medicine use among older adults experiencing polypharmacy in Australia	13
COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions	13
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients	13
Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta‐analysis of observational studies with methodological considerations	13
Combination therapies for COVID‐19: An overview of the clinical trials landscape	13
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment	13
Traditional medicines for COVID‐19: Perspectives from clinical pharmacologists	13
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐bl	13
Challenges and opportunities to include patient‐centric product design in industrial medicines development to improve therapeutic goals	13
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	13
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP	13
Real‐world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population‐based study	13
Improvement of dental prescribing practices using education and a prescribing tool: A pilot intervention study	13
A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status	13
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis	13
Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response	13
Challenges of drug development during the COVID‐19 pandemic: Key considerations for clinical trial designs	13
Evaluation of long‐term detection trends of new psychoactive substances in pooled urine from city street portable urinals (London, UK)	13
Would they trust it? An exploration of psychosocial and environmental factors affecting prescriber acceptance of computerised dose‐recommendation software	13
Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial	13
Cognitive decline associated with anticholinergics, benzodiazepines and Z‐drugs: Findings from The Irish Longitudinal Study on Ageing (TILDA)	13
Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus	13
Nonmedical use of benzodiazepines and Z‐drugs in the UK	13
Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19	13
Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies	13
Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity	13
Mapping the construct and measurement of medication literacy: A scoping review	12
Evaluation of pharmacokinetic‐pharmacodynamic relationships and selection of drug combinations for tuberculosis	12
Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug–drug interactions, renal impairment and paediatric populations	12
Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper	12
Risk of congenital malformations in offspring of women using β‐blockers during early pregnancy: An updated meta‐analysis of observational studies	12
Cost‐utility and cost‐effectiveness analysis of a clinical medication review focused on personal goals in older persons with polypharmacy compared to usual care: Economic evaluation of the DREAMeR stu	12
Extensive hard palate hyperpigmentation associated with chloroquine use	12
Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers	12
A multicentre prospective study evaluating the impact of proton‐pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations	12
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics	12
COVID‐19 vaccines: the importance of transparency and fact‐based education	12
A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk	12
Development of prescribing safety indicators related to mental health disorders and medications: Modified e‐Delphi study	12
MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection	12
Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs	12
A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy	12
Pharmacist‐led intervention on chronic pain management: A systematic review and meta‐analysis	12
Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis	12
Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection	12
Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials	12
Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects	12
Appropriate and inappropriate polypharmacy—Choosing the right strategy	12
Fatalities associated with gabapentinoids in England (2004–2020)	12
Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia	12
Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease	12
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP	12
Population pharmacokinetics of vancomycin in patients with external ventricular drain‐associated ventriculitis	12
Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis	12
Antihistamine‐related deaths in England: Are the high safety profiles of antihistamines leading to their unsafe use?	12
Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity	12
Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens	12
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	12
Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT)	12
The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia	12
Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure	12
Effectiveness of a targeted and tailored pharmacist‐led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled tr	12
Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B‐cell lymphoma: Current state of the art and unmet clinical needs	12
Effective low–dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach–Merritt phenomenon in young infants	11
Amoxicillin‐induced crystal nephropathy: A nationwide French pharmacovigilance databases study	11
Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study	11
Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand	11
Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study	11
The impact of the global COVID‐19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis	11
Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach	11
Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System	11
Deprescribing: What do we know, and where to next?	11
A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis	11
A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments	11